Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb;136(2):125-126.
doi: 10.1016/j.amjmed.2022.09.010. Epub 2022 Sep 26.

Pharmacist-Led Education for Increasing Physician Comfort Prescribing Oral COVID-19 Antivirals

Angela N Coulter  1 , Michael A Campbell Jr  1 , Daniel T Ilges  2 , Augustine S Chavez  3
Affiliations
Editorial

Pharmacist-Led Education for Increasing Physician Comfort Prescribing Oral COVID-19 Antivirals

Angela N Coulter et al. Am J Med. 2023 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Pharmacist-led oral COVID-19 physician education. COVID = coronavirus disease.
See this image and copyright information in PMC

References

    1. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Available at: https://www.fda.gov/media/155050/download. Accessed May 25, 2022.
    1. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. Available at: https://www.fda.gov/media/155054/download. Accessed May 26, 2022.
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542. - DOI - PMC - PubMed
    1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi: 10.1056/NEJMoa2116044. - DOI - PMC - PubMed
    1. Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19a meta-analysis. Ann Med. 2022;54(1):516–523. doi: 10.1080/07853890.2022.2034936. - DOI - PMC - PubMed

Publication types

Substances